Cambridge-based biotech startup TRIMTECH Therapeutics has secured an additional €12 million ($14 million) in Seed funding, bringing the total size of its Seed round to €41 million ($47 million). The fresh capital will accelerate development of its novel protein-degradation therapies targeting neurodegenerative diseases.
The extension round was led by Johnson & Johnson Innovation – JJDC, Inc. and BGF, who join existing investors in supporting the company’s expansion.
Targeting Protein Aggregation in Brain Diseases
TRIMTECH Therapeutics is developing small molecule therapies designed to degrade protein aggregates associated with neurodegenerative conditions such as Alzheimer’s disease and other CNS disorders.
The company’s approach focuses on selectively targeting disease-causing protein assemblies while preserving normal protein function, a key challenge in next-generation drug development.
Seed Extension Strengthens Investor Syndicate
With this latest investment, TRIMTECH’s Seed round now totals €41 million, reflecting strong investor confidence in its platform and scientific direction.
New investors JJDC and BGF will also join the company’s board as non-executive directors, strengthening governance and strategic guidance as the company advances toward clinical development.
Building on the TRIMTAC and TRIMGLUE Platforms
TRIMTECH’s technology is built on decades of academic research into TRIM21, a naturally occurring E3 ligase enzyme.
The company’s proprietary platforms, including TRIMTAC and TRIMGLUE, are designed to:
- Enable targeted degradation of disease-causing proteins
- Preserve healthy monomeric protein function
- Expand small-molecule drug options for previously hard-to-treat diseases
These mechanisms aim to replicate some of the benefits of biologics while maintaining the scalability and accessibility of small-molecule therapeutics.
Tackling High-Impact Neurodegenerative Diseases
Neurodegenerative disorders represent one of the largest unmet needs in global healthcare, with more than 55 million people affected by Alzheimer’s disease alone.
TRIMTECH’s platform is aimed at addressing this growing burden by developing therapies that intervene directly in the protein misfolding and aggregation processes underlying disease progression.
Strong Academic and Institutional Foundations
Founded in 2023, TRIMTECH Therapeutics emerged from leading UK academic institutions, including:
- MRC Laboratory of Molecular Biology
- UK Dementia Research Institute, University of Cambridge
The founding team includes prominent scientists Leo James and Will McEwan, alongside experienced biotech investors and operators from Cambridge Innovation Capital and the Dementia Discovery Fund.
Part of a Broader Neurodegeneration Investment Wave
The Seed extension reflects a wider European trend of increased funding for CNS-focused biotech and protein degradation platforms, alongside growing interest in precision molecular therapies for neurodegenerative diseases.
Recent activity in the sector includes multiple early-stage and Series B financings across protein degradation, AI-driven drug discovery, and CNS delivery platforms.
Moving Toward Clinical Translation
With new capital secured, TRIMTECH plans to advance its pipeline of CNS-penetrant degraders and progress toward preclinical and early clinical milestones.
The company is positioning its platform as a potential foundation for a new class of targeted neurodegenerative disease treatments, addressing conditions that currently lack disease-modifying therapies.
As investor interest in brain health and protein modulation continues to rise, TRIMTECH’s expanded Seed round places it among the better-capitalized early-stage biotech companies in Europe’s neuroscience innovation landscape.
